RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Weaker technical forecast for Spark Therapeutics as stock downgraded to Hold/Accumulate.
(Updated on Jan 24, 2020)

Buy or Hold candidate since Dec 16, 2019 PDF

No changes to the price of Spark Therapeutics stock on the last trading day (Friday, 24th Jan 2020). During the last trading day the stock fluctuated 0% from a day low at $113.57 to a day high of $113.57. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The stock lies in the middle of a narrow and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 4.00% during the next 3 months and, with a 90% probability hold a price between $116.56 and $119.73 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ONCE Signals & Forecast

The Spark Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $113.57 and $112.91. A breakdown below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, January 23, 2020, and so far it has fallen 0%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Spark Therapeutics stock

Spark Therapeutics finds support from accumulated volume at $109.99 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved $0 between high and low, or 0%. For the last week the stock has had daily average volatility of 0%

Our recommended stop-loss: $109.03 (-4.00%) (This stock has low daily movements and this gives low risk. There is a sell signal from a pivot top found 1 day ago.)

Trading Expectations (ONCE) For The Upcoming Trading Day Of Monday 27th

For the upcoming trading day on Monday, 27th we expect Spark Therapeutics to open at $113.57, and during the day (based on 14 day Average True Range), to move between $113.40 and $113.74, which gives a possible trading interval of +/-$0.173 (+/-0.15%) up or down from last closing price. If Spark Therapeutics takes out the full calculated possible swing range there will be an estimated 0.30% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $109.99, some $3.58 (3.15%) from the current price of $113.57, our system finds the risk reward attractive.

Is Spark Therapeutics stock A Buy?

Spark Therapeutics holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold/Accumulate candidate.

Current score: 0.790 Hold/Accumulate Downgraded

Predicted Opening Price for Spark Therapeutics of Monday, January 27, 2020

Fair opening price January 27, 2020 Current price
$113.57 ( 0%) $113.57

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ONCE

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 113.57 .
R2 113.57 .
R1 113.57 .
Current price: 113.57
Support S1 113.57 .
S2 113.57 .
S3 113.57 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 0 .
R1 0 .
Current price 113.57
Support S1 109.99 -3.15%
S2 109.00 -4.02%
S3 108.99 -4.03%

FAQ

What is the symbol for Spark Therapeutics Stock and on which exchange is it traded?
The symbol for Spark Therapeutics is ONCE and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Spark Therapeutics Stock?
Spark Therapeutics holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold/Accumulate candidate.

How to buy Spark Therapeutics Stock?
Spark Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Spark Therapeutics Stock.

What's the current price of Spark Therapeutics Stock?
As of the end of day on the 2020-01-24, the price of an Spark Therapeutics (ONCE) share was $113.57.

What is the 52-week high and low for Spark Therapeutics Stock?
The 52-week high for Spark Therapeutics Stock is $114.20 and the 52-week low is $40.64.
Click to get the best stock tips daily for free!

About Spark Therapeutics

Spark Therapeutics Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia... ONCE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT